Analyst Price Targets — AMED
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 25, 2024 9:41 am | Frank Morgan | RBC Capital | $100.00 | $92.16 | StreetInsider | Amedisys (AMED) PT Raised to $100 at RBC Capital |
| July 6, 2023 8:43 am | Brian Tanquilut | Jefferies | $90.80 | $91.28 | Benzinga | Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday |
| January 5, 2023 6:56 am | — | Leerink Partners | $85.00 | $86.00 | Benzinga | SVB Leerink Maintains Market Perform on Amedisys, Lowers Price Target to $85 |
| November 11, 2022 9:52 am | — | Stephens | $106.00 | $91.78 | Benzinga | Stephens & Co. Maintains Equal-Weight on Amedisys, Lowers Price Target to $106 |
| July 26, 2022 7:45 pm | David MacDonald | Truist Financial | $150.00 | $128.18 | Pulse 2.0 | Amedisys (AMED) Stock: $150 Target And Buy Rating |
| July 3, 2022 7:23 pm | Justin Bowers | Deutsche Bank | $175.00 | $110.82 | Pulse 2.0 | Amedisys (AMED) Stock: $175 Target And Buy Rating |
| April 29, 2022 9:21 am | — | Credit Suisse | $182.00 | $131.13 | Benzinga | Credit Suisse Maintains Outperform on Amedisys, Raises Price Target to $182 |
| April 29, 2022 9:09 am | — | Raymond James | $180.00 | $128.41 | Benzinga | Raymond James Maintains Outperform on Amedisys, Lowers Price Target to $180 |
| April 29, 2022 7:00 am | — | Leerink Partners | $131.00 | $131.89 | Benzinga | SVB Leerink Maintains Market Perform on Amedisys, Lowers Price Target to $131 |
| February 25, 2022 12:00 am | Matthew Borsch | BMO Capital | $190.00 | $159.90 | StreetInsider | UPDATE: BMO Capital upgrades Amedisys (AMED) to Outperform |
No recent news available for AMED.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMED.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.